An estimated 350,000 people living with HIV in developing countries have been forced off their life-saving antiretroviral medications as a direct consequence of the Trump administration's foreign aid cuts, according to data compiled by international health organizations including the Global Fund to Fight AIDS, Tuberculosis and Malaria and Doctors Without Borders. The interruption of treatment is not merely a setback for individual patients but a potential threat to decades of progress against the global HIV epidemic, as treatment interruptions increase the risk of drug resistance developing and enable individuals to become infectious again.

Scale of the PEPFAR Cuts

The US President's Emergency Plan for AIDS Relief, known as PEPFAR, has been one of the most successful US foreign policy investments in history, providing antiretroviral treatment to over 20 million people globally since its launch in 2003. The program is credited by independent evaluations with saving over 25 million lives. The Trump administration's cuts to PEPFAR and related global health programs have been implemented at a speed and scale that has overwhelmed the capacity of alternative funders to compensate, leaving hundreds of thousands of patients without access to the medications that are keeping them alive and preventing HIV transmission.

Consequences of Treatment Interruption

For people living with HIV, interruption of antiretroviral therapy has serious and potentially fatal consequences. Without medication, viral loads increase rapidly, compromising immune function and increasing susceptibility to opportunistic infections. People who are on treatment and maintaining undetectable viral loads cannot transmit the virus; when treatment is interrupted and viral loads rise, they become infectious again, threatening partners and creating conditions for new transmissions. In communities with high HIV prevalence and limited healthcare capacity, treatment interruptions at scale could trigger new epidemic cycles that would cost far more to address than the original treatment investment.

Global Response Challenges

The scale of the funding gap created by US withdrawal from global health programs has exceeded the capacity of other donors to compensate. The Global Fund, which relies on contributions from multiple governments, has initiated emergency appeals, and several European countries have pledged additional contributions, but the sums involved cannot replace the full magnitude of US contributions. Program administrators have been forced to make devastating triage decisions about which patients to continue treating and which to discharge, decisions with direct life-and-death consequences.

Long-Term Public Health Consequences

Beyond the immediate individual consequences for patients losing treatment access, the disruption of global HIV programs has long-term public health consequences that will extend for decades. Progress toward the UNAIDS goal of ending AIDS as a public health threat by 2030 has been set back years by the funding disruptions. The development of drug-resistant HIV strains in under-treated populations creates challenges for future treatment efforts. And the erosion of health system capacity and trust that accompanies program failures makes future public health interventions more difficult to implement effectively.